# EDGAR Filing Document

**Accession Number:** 0001390478
**File Stem:** 0001104659-25-076886
**Filing Date:** 2025-8
**Character Count:** 21998
**Document Hash:** a70d8ef5dc642b3a262e7034e899fdb6
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-076886.hdr.sgml**: 20250812

**ACCESSION NUMBER**: 0001104659-25-076886

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 15

**FILED AS OF DATE**: 20250812

**DATE AS OF CHANGE**: 20250812

**EFFECTIVENESS DATE**: 20250812

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SELLAS Life Sciences Group, Inc.
- **CENTRAL INDEX KEY:** 0001390478
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-289534
- **FILM NUMBER:** 251207370

**BUSINESS ADDRESS:**
- **STREET 1:** 7 TIMES SQUARE
- **STREET 2:** SUITE 2503
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10036
- **BUSINESS PHONE:** 6462005278

**MAIL ADDRESS:**
- **STREET 1:** 7 TIMES SQUARE
- **STREET 2:** SUITE 2503
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10036

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Galena Biopharma, Inc.
- **DATE OF NAME CHANGE:** 20110926

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** RXi Pharmaceuticals Corp
- **DATE OF NAME CHANGE:** 20110926

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GALENA BIOPHARMA, INC.
- **DATE OF NAME CHANGE:** 20110922

As filed with the Securities and Exchange Commission on August 12, 2025

**Registration No. 333-**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**_______________**

**FORM S-8**

**REGISTRATION STATEMENT<br> UNDER<br> THE SECURITIES ACT OF 1933**

**_______________**

**SELLAS Life Sciences Group, Inc.** 

(Exact name of registrant as specified in its charter)

_______________

---

| | |
|:---|:---|
| &nbsp;&nbsp; **Delaware** | &nbsp;&nbsp; **20-8099512** |
| &nbsp;&nbsp;(State or other jurisdiction<br> of incorporation or organization) | &nbsp;&nbsp;(I.R.S. Employer<br> Identification No.) |

---

**7 Times Square, Suite 2503<br> New York, NY 10036**

(Address of Principal Executive Offices) (Zip Code)

_______________

**SELLAS Life Sciences Group, Inc. Amended and Restated 2021 Employee Stock Purchase Plan**

(Full title of the plan)

_______________

**Angelos M. Stergiou, M.D., ScD h.c.**

**President and Chief Executive Officer**

**SELLAS Life Sciences Group, Inc.**

**7 Times Square, Suite 2503**

**New York, NY 10036**

**Telephone: (640) 200-5278**

*(Name and address of agent for service)*

*(Telephone number, including area code, of agent for service)*

**Copies to:**

**Joel I. Papernik, Esq.**

**Daniel A. Bagliebter, Esq.**

**Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.**

**919 Third Avenue, New York, NY 10022**

**(212) 935-3000**

_______________

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**<u> </u>**

**<u>EXPLANATORY NOTE</u>**

SELLAS Life Sciences Group, Inc. (the "Registrant") has prepared this Registration Statement on Form S-8 (the "Registration Statement") in accordance with the requirements of Form S-8 under the Securities Act of 1933, as amended (the "Securities Act"), to register 800,000 additional shares of common stock, par value $0.0001 per share ("Common Stock"), for issuance under the SELLAS Life Sciences Group, Inc. Amended and Restated 2021 Employee Stock Purchase Plan (the "Plan"), representing an increase of 800,000 shares reserved under the Plan, as approved by the Registrant's stockholders at the Registrant's annual meeting of stockholders on June 17, 2025.

This Registration Statement registers additional securities of the same class as other securities for which the registration statement filed on Form S-8 (SEC File Nos. 333-237168, 333-258799, 333-264899, 333-270608, and 333-276615) of the Registrant is effective. The information contained in the Registrant's registration statements on Form S-8 filed with the Securities and Exchange Commission on [March 13, 2020](https://www.sec.gov/Archives/edgar/data/1390478/000110465920033156/tm2012700d1_s8.htm) (File No. 333-237168), [August 13, 2021](https://www.sec.gov/Archives/edgar/data/1390478/000110465921105068/tm2124794d1_s8.htm) (File No. 333-258799), [May 12, 2022](https://www.sec.gov/Archives/edgar/data/1390478/000110465922059557/tm2215052d1_s8.htm) (File No. 333-264899), [March 16, 2023](https://www.sec.gov/Archives/edgar/data/1390478/000110465923033333/tm239579d1_s8.htm) (File No. 333-270608), and [January 19, 2024](https://www.sec.gov/Archives/edgar/data/1390478/000110465924005211/tm2323158d1_s8.htm) (333-276615) is hereby incorporated by reference pursuant to General Instruction E of Form S-8.

**PART II** 

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT** 

<u>Item 8. Exhibits</u>.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Exhibit<br> Number** | **Exhibit Description** | **Filed<br> Herewith** | **Incorporated by<br> Reference herein from<br> Form or Schedule** | **Filing Date** | **SEC File/<br> Reg.<br> Number** |
| [3.1](https://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex31.htm) | [Composite Amended and Restated Certificate of Incorporation of the Registrant (formerly, Galena Biopharma, Inc.), amended as of December 27, 2017](https://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex31.htm) |  | [Form 10-K<br> (Exhibit 3.1)](https://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex31.htm) | [April 13, 2018](https://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex31.htm) | [001-33958](https://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex31.htm) |
| [3.2](https://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex31.htm) | [Certificate of Amendment to the Amended and Restated Certificate of Incorporation](https://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex31.htm) |  | [Form 10-K<br> (Exhibit 3.3)](https://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex31.htm) | [March 23, 2021](https://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex31.htm) | [001-33958](https://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex31.htm) |
| [3.3](https://www.sec.gov/Archives/edgar/data/1390478/000119312518004463/d515897dex33.htm) | [Amended and Restated By-Laws of the Registrant](https://www.sec.gov/Archives/edgar/data/1390478/000119312518004463/d515897dex33.htm) |  | [Form 8-K <br> (Exhibit 3.3)](https://www.sec.gov/Archives/edgar/data/1390478/000119312518004463/d515897dex33.htm) | [January 5, 2018](https://www.sec.gov/Archives/edgar/data/1390478/000119312518004463/d515897dex33.htm) | [001-33958](https://www.sec.gov/Archives/edgar/data/1390478/000119312518004463/d515897dex33.htm) |
| [5.1](tm2523289d1_ex5-1.htm) | [Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.](tm2523289d1_ex5-1.htm) | [X](tm2523289d1_ex5-1.htm) |  |  |  |
| [23.1](tm2523289d1_ex23-1.htm) | [Consent of Baker Tilly US, LLP, independent registered public accounting firm.](tm2523289d1_ex23-1.htm) | [X](tm2523289d1_ex23-1.htm) |  |  |  |
| [23.2](tm2523289d1_ex5-1.htm) | [Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in Exhibit 5.1)](tm2523289d1_ex5-1.htm) | [X](tm2523289d1_ex5-1.htm) |  |  |  |
| [24.1](#poa) | [Power of Attorney (included on the signature page hereof)](#poa) | [X](#poa) |  |  |  |
| [99.1+](https://www.sec.gov/Archives/edgar/data/1390478/000139047825000016/sls-20250630ex101.htm) | [SELLAS Life Sciences Group, Inc. Amended and Restated 2021 Employee Stock Purchase Plan](https://www.sec.gov/Archives/edgar/data/1390478/000139047825000016/sls-20250630ex101.htm) |  | [Form 10-Q<br> (Exhibit 10.1)](https://www.sec.gov/Archives/edgar/data/1390478/000139047825000016/sls-20250630ex101.htm) | [August 12, 2025](https://www.sec.gov/Archives/edgar/data/1390478/000139047825000016/sls-20250630ex101.htm) | [001-33958](https://www.sec.gov/Archives/edgar/data/1390478/000139047825000016/sls-20250630ex101.htm) |
| [107](tm2523289d1_ex107.htm) | [Filing Fee Table](tm2523289d1_ex107.htm) | [X](tm2523289d1_ex107.htm) |  |  |  |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, New York, on August 12, 2025.

---

| | |
|:---|:---|
| **SELLAS LIFE SCIENCES GROUP, INC.** | **SELLAS LIFE SCIENCES GROUP, INC.** |
| By: | /s/ Angelos M. Stergiou |
| Angelos M. Stergiou, M.D., ScD h.c. | Angelos M. Stergiou, M.D., ScD h.c. |
| President and Chief Executive Officer | President and Chief Executive Officer |

---

Each person whose signature appears below constitutes and appoints each of Angelos M. Stergiou and John T. Burns, acting alone or together with another attorney-in-fact, as his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for such person and in his or her name, place and stead, in any and all capacities, to sign any or all further amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof. Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the date indicated.

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp; **Signature** | &nbsp;&nbsp; **Title** | &nbsp;&nbsp; **Date** |
| &nbsp;&nbsp; /s/ Angelos M. Stergiou | &nbsp;&nbsp;President, Chief Executive Officer and Director (Principal Executive Officer) | &nbsp;&nbsp;August 12, 2025 |
| &nbsp;&nbsp;Angelos M. Stergiou, M.D., ScD h.c. | &nbsp;&nbsp;President, Chief Executive Officer and Director (Principal Executive Officer) | &nbsp;&nbsp;August 12, 2025 |
| &nbsp;&nbsp; /s/ John T. Burns | &nbsp;&nbsp;Senior Vice President, Chief Financial Officer (Principal Financial and Accounting Officer) | &nbsp;&nbsp;August 12, 2025 |
| &nbsp;&nbsp;John T. Burns |  |  |
| &nbsp;&nbsp; /s/ John Varian | &nbsp;&nbsp;Chair of the Board of Directors | &nbsp;&nbsp;August 12, 2025 |
| &nbsp;&nbsp;John Varian |  |  |
| &nbsp;&nbsp; /s/ David Scheinberg | &nbsp;&nbsp;Director | &nbsp;&nbsp;August 12, 2025 |
| &nbsp;&nbsp;David Scheinberg, M.D., PhD. |  |  |
| &nbsp;&nbsp; /s/ Robert Van Nostrand | &nbsp;&nbsp;Director | &nbsp;&nbsp;August 12, 2025 |
| &nbsp;&nbsp;Robert Van Nostrand |  |  |
| &nbsp;&nbsp; /s/ Jane Wasman | &nbsp;&nbsp;Director | &nbsp;&nbsp;August 12, 2025 |
| &nbsp;&nbsp;Jane Wasman |  |  |
| &nbsp;&nbsp; /s/ Katherine Kalin | &nbsp;&nbsp;Director | &nbsp;&nbsp;August 12, 2025 |
| &nbsp;&nbsp;Katherine Kalin |  |  |

---

## Exhibit 5.1

**Exhibit 5.1**

---

| | |
|:---|:---|
| ![](image_001.jpg) | 919 Third Avenue<br> New York, NY 10022<br> 212 935 3000<br> mintz.com |

---

August 12, 2025

SELLAS Life Sciences Group, Inc.

7 Times Square, Suite 2503

New York, New York 10036

Re: Registration Statement on Form S-8

Ladies and Gentlemen:

We have acted as legal counsel to SELLAS Life Sciences Group, Inc., a Delaware corporation (the "Company"), in connection with the preparation and filing with the Securities and Exchange Commission (the "Commission") of a Registration Statement on Form S-8 (the "Registration Statement"), pursuant to which the Company is registering the issuance under the Securities Act of 1933, as amended (the "Securities Act"), of an aggregate of 800,000 shares (the "Shares") of the Company's common stock, par value $0.0001 per share (the "Common Stock"), that may be issued pursuant to the Company's Amended and Restated 2021 Employee Stock Purchase Plan (the "Plan"). This opinion is being rendered in connection with the filing of the Registration Statement with the Commission. All capitalized terms used herein and not otherwise defined shall have the respective meanings given to them in the Registration Statement.

In connection with this opinion, we have examined the Company's Amended and Restated Certificate of Incorporation and the Company's Amended and Restated Bylaws, each as currently in effect; such other records of the corporate proceedings of the Company as we have deemed relevant; and the Registration Statement and the exhibits thereto.

In our examination, we have assumed the genuineness of all signatures, the legal capacity of natural persons, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as copies, the authenticity of the originals of such copies, and the truth and correctness of any representations and warranties contained therein. In addition, we have assumed that the Company will receive any required consideration in accordance with the terms of the Plan.

Our opinion expressed herein is limited to the General Corporation Law of the State of Delaware and we express no opinion with respect to the laws of any other jurisdiction. No opinion is expressed herein with respect to the qualification of the Shares under the securities or blue sky laws of any state or any foreign jurisdiction.

Please note that we are opining only as to the matters expressly set forth herein, and no opinion should be inferred as to any other matters. This opinion is based upon currently existing statutes, rules, regulations and judicial decisions, and we disclaim any obligation to advise you of any change in any of these sources of law or subsequent legal or factual developments which might affect any matters or opinions set forth herein.

Based upon the foregoing, we are of the opinion that the Shares, when issued and delivered in accordance with the terms of the Plan, will be validly issued, fully paid and non-assessable.

**MINTZ**

August 12, 2025

We understand that you wish to file this opinion with the Commission as an exhibit to the Registration Statement in accordance with the requirements of Item 601(b)(5) of Regulation S-K promulgated under the Securities Act, and we hereby consent thereto. In giving this consent, we do not admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission promulgated thereunder.

---

| |
|:---|
| Very truly yours, |
| /s/ Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. |
| Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. |

---

Boston Los Angeles New York San Diego San Francisco toronto Washington

MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO, P.C.

## Exhibit 23.1

**Exhibit 23.1**

**Consent of Independent Registered Public Accounting Firm**

We consent to the incorporation by reference in this Registration Statement on Form S-8 of SELLAS Life Sciences Group, Inc. (the "Company"), of our report dated March 20, 2025, relating to the consolidated financial statements of the Company (which report expresses an unqualified opinion and includes an explanatory paragraph relating to a going concern emphasis) appearing in the Annual Report on Form 10-K of the Company for the year ended December 31, 2024, filed with the Securities and Exchange Commission.

/s/ Baker Tilly US, LLP

Campbell, California

August 12, 2025

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **SELLAS Life Sciences Group, Inc.**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Type**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Class Title**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Calculation Rule**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount Registered**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Proposed Maximum Offering Price Per Unit**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Maximum Aggregate Offering Price**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Rate**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount of Registration Fee**  |
| 1 | Equity | Common stock, par value $0.0001 per share | 457(a) | 800000 | $1.58 | $1264000.00 | 0.0001531 | $193.52 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $1264000.00  |  | $193.52  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $193.52  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Offering Note** <br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1</sup> The number of shares of common stock, par value $0.0001 per share ("common stock"), of SELLAS Life Sciences Group, Inc. (the "Registrant") stated above consists of additional shares of common stock available for issuance under the 2023 Amended and Restated Equity Incentive Plan (the "Plan"), as approved by the Registrant's stockholders at the Registrant's annual meeting of stockholders on June 17, 2025. The maximum number of shares which may be sold upon the exercise of options or issuance of stock-based awards granted under the Plan is subject to adjustment in accordance with certain anti-dilution and other provisions of the Plan. Accordingly, pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement covers, in addition to the number of shares stated above, an indeterminate number of shares which may be subject to grant or otherwise issuable after the operation of any such anti-dilution and other provisions. Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) and Rule 457(h) promulgated under the Securities Act. The offering price per share and the aggregate offering price for shares reserved for future grant or issuance under the Plan are based on the average of the high and the low price of Registrant's common stock as reported on The Nasdaq Capital Market as of a date (August 11, 2025) within five business days prior to filing this Registration Statement.

---

| | |
|:---|:---|
| | |
| **Rule 457(p)** | **Rule 457(p)** |
| Fee Offset Claims | N/A |
| Fee Offset Sources | N/A |

---